Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Moderna announced that its experimental shot was nearly 84 percent effective at preventing respiratory syncytial virus symptoms in a large study of adults 60 years and older. The drugmaker plans to ...

Moderna旗下mRNA疫苗再获FDA批准Moderna日前宣布，美国FDA已批准该公司的呼吸道合胞病毒（RSV）疫苗mRESVIA（mRNA-1345），用于预防18-59岁高风险人群的RSV相关下呼吸道疾病（LRTD）。这一批准扩大了mRESV ...

In other developments, the ECDC today reported a slow rise in COVID activity in the Europe, which may partly reflect waning ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Days after Health and Human Services Secretary Robert F. Kennedy Jr. purged the Centers for Disease Control and Prevention’s ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

US mRNA specialist Moderna today announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), ...